Eversept Partners portfolio
Investment firmPortfolio as of Jun 30, 2026 (Q2 2026) · filed with the SEC on Aug 14, 2026 · data updated on Nov 5, 2026 · Q2 2026 13F (filing) ↗ · all its 13F filings ↗
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Eversept Partners reported a $1.8 bn portfolio of 115 positions to the SEC as of the end of Q2 2026. Its largest positions are UTHR, ABVX, EHC. During the quarter it opened CareTrust REIT and UnitedHealth Group and exited Healthpeak Properties and Avantor.
Sections with a free account
What changed this quarter
122 positions with a change (30 new, 37 added to, 37 trimmed, 18 sold); also, 1 entered through an IPO, 2 exited through an acquisition or merger. 12 are listed here: those of 0.5 points of the portfolio or more (up to 12).
- Ensign Group+3,979%more sharesIncreased0.2% → 5.3%
- Encompass Health+429%more sharesIncreased1.2% → 5.7%
- GSK−73%fewer sharesReduced6.5% → 1.4%
- Natera−54%fewer sharesReduced5.1% → 2.6%
- CareTrust REIT+2.4 ppof portfolioNew— → 2.4%
- Healthpeak Properties−1.8 ppof portfolioSold out2.1% → —
- Avantor−1.3 ppof portfolioSold out1.5% → —
- Qiagen−1.2 ppof portfolioSold out1.4% → —
- UnitedHealth Group+1.2 ppof portfolioNew— → 1.2%
- Welltower−52%fewer sharesReduced2.4% → 1.1%
- Liquidia−37%fewer sharesReduced1.7% → 1.9%
- Cogent Biosciences+1.0 ppof portfolioNew— → 1.0%
The figure on the right: for positions added to or trimmed, the change in the number of shares (%); for new and sold ones, the points of the portfolio moved (pp). Below, the portfolio weight before → after. Traded weight: what it bought or sold, excluding price effects.
Top holdings
- United TherapeuticsUTHR8.5%
- AbivaxABVX6.6%
- Encompass HealthEHC5.7%
- Ensign GroupENSG5.3%
- Vera TherapeuticsVERA5.2%
- Celldex TherapeuticsCLDX3.6%
- Syndax PharmaceuticalsSNDX3.3%
- Brookdale Senior LivingBKD3.0%
- Ionis PharmaceuticalsIONS2.9%
- NateraNTRA2.6%
- Travere TherapeuticsTVTX2.5%
- CareTrust REITCTRE2.4%
- HCA HealthcareHCA2.1%
- VaxcytePCVX2.0%
- LiquidiaLQDA1.9%
“Since”: first quarter of the current run, unbroken until today. In the details, prices are the quarter-end prices of the quarters in which it added shares, per the 13F. The manager may have bought at any price within each quarter; the SEC only publishes the value at quarter end.
Portfolio by sector
- ● Health Care 93%
- ● Real Estate 6%
- ● Industrials 1%
How its portfolio changed (8 quarters)
Q2 2026: 115
Q2 2026: 47%
Q2 2026: 25.9%
Traded turnover: the weight it bought plus the weight it sold in the quarter, divided by two, excluding price moves. The plain “turnover” in the header does include that effect. With a free account: the full history and sectors over time.
Declared options (5)
Besides stocks, Eversept Partners declared 3 puts (they gain if the stock falls) and 2 calls (they gain if it rises) with a notional of $93.3M. The 13F reports the value of the underlying shares, not the premium paid, so these figures look large and are not added to the portfolio. Nor does it say whether the option is bought or written, or its strike or expiry: it may be a hedge.
- PUTInvesco QQQ Trust Series 1 ETFQQQ$72.6M
- CALLInsmedINSM$10.3M
- PUTState Street SPDR S&P Biotech ETFXBI$4.9M
- PUTUniversal Health ServicesUHS$2.8M
- CALLQiagenQGEN$2.7M
Stakes above 5% (13D/13G)
Companies where this filer reported holding 5% or more of the shares. It is the figure from its latest filing on each one; history since December 2024.
How we classify it
Investment firm, per its Form ADV of Mar 31, 2026 (high confidence).
The data, as reported: EVERSEPT PARTNERS, L.P. (CRD 282358): 7.B private funds: 3 hedge (gross assets $2.3 bn); 5.D assets by client type: pooled vehicles 99% (of $2.7 bn)
The type comes from a rule applied to that data. If it looks wrong, tell us.
Not counted as a concentrated manager: its portfolio is not within 5 to 100 positions. Its portfolio is shown all the same, but it is left out of manager counts, the consensus and the ranking. How this is decided
Similar managers by type and size
Same type of filer and a 13F portfolio value between a third and three times this one. It is not a comparison of what they hold.
- Spyglass Capital ManagementInvestment firm · $1.8 bn
- Kynam Capital ManagementInvestment firm · $1.8 bn
- Keystone Investors PTEInvestment firm · $1.9 bn
- Trinity Street Asset Management LLPInvestment firm · $1.9 bn
- Sofinnova InvestmentsInvestment firm · $1.9 bn
- Black Creek Investment ManagementInvestment firm · $1.8 bn